Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2011, Article ID 704015, 5 pages
http://dx.doi.org/10.4061/2011/704015
Review Article

Biochemical Bone Turnover Markers and Osteoporosis in Older Men: Where Are We?

INSERM UMR 1033, Université de Lyon, Hôpital Edouard Herriot, Pavillon F, Place d'Arsonval, 69437 Lyon, France

Received 29 May 2011; Revised 8 November 2011; Accepted 12 November 2011

Academic Editor: S. Minisola

Copyright © 2011 Pawel Szulc. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Szulc, J. M. Kaufman, and P. D. Delmas, “Biochemical assessment of bone turnover and bone fragility in men,” Osteoporosis International, vol. 18, no. 11, pp. 1451–1461, 2007. View at Publisher · View at Google Scholar · View at PubMed
  2. S. Vasikaran, C. Cooper, R. Eastell et al., “International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 8, pp. 1271–1274, 2011. View at Publisher · View at Google Scholar · View at PubMed
  3. P. Szulc, P. Garnero, F. Munoz, F. Marchand, and P. D. Delmas, “Cross-sectional evaluation of bone metabolism in men,” Journal of Bone and Mineral Research, vol. 16, no. 9, pp. 1642–1650, 2001. View at Google Scholar
  4. D. L. Schneider and E. L. Barrett-Connor, “Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density,” Archives of Internal Medicine, vol. 157, no. 11, pp. 1241–1245, 1997. View at Google Scholar
  5. P. Szulc, A. Montella, and P. D. Delmas, “High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study,” Annals of the Rheumatic Diseases, vol. 67, no. 9, pp. 1249–1255, 2008. View at Publisher · View at Google Scholar · View at PubMed
  6. D. C. Bauer, P. Garnero, S. L. Harrison et al., “Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study,” Journal of Bone and Mineral Research, vol. 24, no. 12, pp. 2032–2038, 2009. View at Publisher · View at Google Scholar · View at PubMed
  7. E. Dennison, R. Eastell, C. H. D. Fall, S. Kellingray, P. J. Wood, and C. Cooper, “Determinants of bone loss in elderly men and women: a prospective population-based study,” Osteoporosis International, vol. 10, no. 5, pp. 384–391, 1999. View at Publisher · View at Google Scholar
  8. H. Luukinen, S. M. Kakonen, K. Pettersson et al., “Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin,” Journal of Bone and Mineral Research, vol. 15, no. 12, pp. 2473–2478, 2000. View at Google Scholar
  9. C. Meier, T. V. Nguyen, J. R. Center, M. J. Seibel, and J. A. Eisman, “Bone resorption and osteoporotic fractures in elderly men: the Dubbo Osteoporosis Epidemiology study,” Journal of Bone and Mineral Research, vol. 20, no. 4, pp. 579–587, 2005. View at Publisher · View at Google Scholar · View at PubMed
  10. D. Bauer, P. Garnero, S. Litwack Harrison et al., “Type I collagen isomerization (Alpha/Beta CTX Ratio) and risk of clinical vertebral fracture in men: a prospective study,” http://www.asbmr.org/Meetings/Annual Meeting/Abstract Detail.aspx?aid=7ed933e3-0487-4b5a-b2dd-747876d1ecde.
  11. P. Qvist, S. Christgau, B. J. Pedersen, A. Schlemmer, and C. Christiansen, “Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting,” Bone, vol. 31, no. 1, pp. 57–61, 2002. View at Publisher · View at Google Scholar
  12. R. Theiler, H. B. Stähelin, M. Kränzlin, A. Tyndall, and H. A. Bischoff, “High bone turnover in the elderly,” Archives of Physical Medicine and Rehabilitation, vol. 80, no. 5, pp. 485–489, 1999. View at Publisher · View at Google Scholar
  13. K. Stoffel, H. Engler, M. Kuster, and W. Riesen, “Changes in biochemical markers after lower limb fractures,” Clinical Chemistry, vol. 53, no. 1, pp. 131–134, 2007. View at Publisher · View at Google Scholar · View at PubMed
  14. D. J. Leeming, M. Koizumi, I. Byrjalsen, B. Li, P. Qvist, and L. B. Tankó, “The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 1, pp. 32–38, 2006. View at Publisher · View at Google Scholar · View at PubMed
  15. A. Dovio, L. Perazzolo, G. Osella et al., “Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 10, pp. 4923–4928, 2004. View at Publisher · View at Google Scholar · View at PubMed
  16. F. Richy, J. Bousquet, G. E. Ehrlich et al., “Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review,” Osteoporosis International, vol. 14, no. 3, pp. 179–190, 2003. View at Publisher · View at Google Scholar · View at PubMed
  17. A. M. Kenny, A. Kleppinger, K. Annis et al., “Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty,” Journal of the American Geriatrics Society, vol. 58, no. 6, pp. 1134–1143, 2010. View at Publisher · View at Google Scholar · View at PubMed
  18. C. Y. Guo, T. H. Jones, and R. Eastell, “Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 2, pp. 658–665, 1997. View at Publisher · View at Google Scholar
  19. J. K. Amory, N. B. Watts, K. A. Easley et al., “Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 503–510, 2004. View at Publisher · View at Google Scholar
  20. C. Wang, R. S. Swerdloff, A. Iranmanesh et al., “Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men,” Clinical Endocrinology, vol. 54, no. 6, pp. 739–750, 2001. View at Publisher · View at Google Scholar
  21. P. J. Snyder, H. Peachey, J. A. Berlin et al., “Effects of testosterone replacement in hypogonadal men,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 8, pp. 2670–2677, 2000. View at Publisher · View at Google Scholar
  22. A. M. Isidori, E. Giannetta, E. A. Greco et al., “Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis,” Clinical Endocrinology, vol. 63, no. 3, pp. 280–293, 2005. View at Publisher · View at Google Scholar · View at PubMed
  23. S. Bhasin, E. J. He, M. Kawakubo et al., “N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 11, pp. 4224–4233, 2009. View at Publisher · View at Google Scholar · View at PubMed
  24. E. Orwoll, M. Ettinger, S. Weiss et al., “Alendronate for the treatment of osteoporosis in men,” New England Journal of Medicine, vol. 343, no. 9, pp. 604–610, 2000. View at Publisher · View at Google Scholar · View at PubMed
  25. K. G. Saag, R. Emkey, T. J. Schnitzer et al., “Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis,” New England Journal of Medicine, vol. 339, no. 5, pp. 292–299, 1998. View at Publisher · View at Google Scholar · View at PubMed
  26. I. Shimon, V. Eshed, R. Doolman, B. A. Sela, A. Karasik, and I. Vered, “Alendronate for osteoporosis in men with androgen-repleted hypogonadism,” Osteoporosis International, vol. 16, no. 12, pp. 1591–1596, 2005. View at Publisher · View at Google Scholar · View at PubMed
  27. S. Boonen, E. S. Orwoll, D. Wenderoth, K. J. Stoner, R. Eusebio, and P. D. Delmas, “Once-weekly risedronate in men with osteoporosis: results of a 2-Year, placebo-controlled, double-blind, multicenter study,” Journal of Bone and Mineral Research, vol. 24, no. 4, pp. 719–725, 2009. View at Publisher · View at Google Scholar · View at PubMed
  28. T. Majima, A. Shimatsu, Y. Komatsu et al., “Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study,” Journal of Bone and Mineral Metabolism, vol. 27, no. 2, pp. 168–174, 2009. View at Publisher · View at Google Scholar · View at PubMed
  29. D. M. Reid, S. Adami, J. P. Devogelaer, and A. A. Chines, “Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy,” Calcified Tissue International, vol. 69, no. 4, pp. 242–247, 2001. View at Publisher · View at Google Scholar
  30. Y. Sato, J. Iwamoto, T. Kanoko, and K. Satoh, “Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke,” Archives of Internal Medicine, vol. 165, no. 15, pp. 1743–1748, 2005. View at Publisher · View at Google Scholar · View at PubMed
  31. Y. Sato, Y. Honda, and J. Iwamoto, “Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease,” Neurology, vol. 68, no. 12, pp. 911–915, 2007. View at Publisher · View at Google Scholar · View at PubMed
  32. J. J. Stepan, P. Burckhardt, and V. Hána, “The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status,” Bone, vol. 33, no. 4, pp. 589–596, 2003. View at Publisher · View at Google Scholar
  33. E. S. Orwoll, N. C. Binkley, E. M. Lewiecki, U. Gruntmanis, M. A. Fries, and G. Dasic, “Efficacy and safety of monthly ibandronate in men with low bone density,” Bone, vol. 46, no. 4, pp. 970–976, 2010. View at Publisher · View at Google Scholar · View at PubMed
  34. E. S. Orwoll, P. D. Miller, J. D. Adachi et al., “Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study,” Journal of Bone and Mineral Research, vol. 25, no. 10, pp. 2239–2250, 2010. View at Publisher · View at Google Scholar · View at PubMed
  35. M. J. Bolland, A. B. Grey, A. M. Horne et al., “Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 4, pp. 1283–1288, 2007. View at Publisher · View at Google Scholar · View at PubMed
  36. J. E. Brown, S. P. Ellis, J. E. Lester et al., “Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid,” Clinical Cancer Research, vol. 13, no. 18, pp. 5406–5410, 2007. View at Publisher · View at Google Scholar · View at PubMed
  37. C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer, and L. V. Lacerna, “Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer,” Journal of Urology, vol. 176, no. 3, pp. 972–978, 2006. View at Publisher · View at Google Scholar · View at PubMed
  38. M. R. Smith, B. Egerdie, N. H. Toriz et al., “Denosumab in men receiving androgen-deprivation therapy for prostate cancer,” New England Journal of Medicine, vol. 361, no. 8, pp. 745–755, 2009. View at Publisher · View at Google Scholar · View at PubMed
  39. M. R. Smith, R. A. Morton, K. G. Barnette et al., “Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer,” Journal of Urology, vol. 184, no. 4, pp. 1316–1321, 2010. View at Publisher · View at Google Scholar · View at PubMed
  40. E. S. Orwoll, W. H. Scheele, S. Paul et al., “The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis,” Journal of Bone and Mineral Research, vol. 18, no. 1, pp. 9–17, 2003. View at Publisher · View at Google Scholar · View at PubMed
  41. E. S. Kurland, F. Cosman, D. J. McMahon, C. J. Rosen, R. Lindsay, and J. P. Bilezikian, “Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 9, pp. 3069–3076, 2000. View at Google Scholar